Eurofins Scientific SE · EURONEXT:ERF

Eurofins Scientific — Investor Presentation (December 2018)

83 slides from Eurofins Scientific's investor presentation, December 2018

  1. Slide 1: Eurofins Corporate Presentation December 2018

    Eurofins A global leader in bioanalytical testing in the food, environment, pharmaceutical, agrosciences and clinical sectors Consistently delivering strong, sustainable, profitable growth Doubled revenues more than 3 times (every 3 years on average) between 2005 and 2017 Sales & EBITDA multiplied b

  2. Slide 2: Disclaimer

    Disclaimer The statements made during this presentation or as response to questions during the Question & Answers period that are not historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on market and competitive information available at a certain

  3. Slide 3: Contents

    Contents  Introduction  Market & Strategic Positioning  Finance & Outlook  Summary  Appendix 3

  4. Slide 4: Eurofins' Mission and key figures

    Eurofins’ Mission is to contribute to global Health, Safety & Environment with the best in bioanalysis  Founded in 1987  IPO in 1997 in Paris at EUR 1.83 per share (vs EUR 476.40 at 29/06/2018) Eurofins provides testing  Over 45,000 employees accross more than 650 laboratories in 45 services in f

  5. Slide 5: Leading market positions in high-growth markets (1/2)

    Leading global and local market positions in attractive high-growth markets* (1/2)… Food & Feed Testing for Environment Clinical Testing Pharma/Biotech/Agrosciences Testing Diagnostics N°1* N°1 to N°3* N°1* Start-Up Eurofins position worldwide worldwide worldwide Start 2014 Start 1987 Start 2000-200

  6. Slide 6: Leading market positions in high-growth markets (2/2)

    Leading global and local market positions in attractive high-growth markets* (2/2) Food & Feed Testing for Environment Clinical Testing Pharma/Biotech/Agrosciences Testing Diagnostics N°1* N°1 to N°3* N°1* Start-Up Eurofins position worldwide worldwide worldwide Start 2014 Start 1987 Start 2000-2005

  7. Slide 7: High barriers to entry reinforcing leadership positions

    Building leadership positions in an industry with significant network effects and competitive advantage for the market leader High level of investment and innovation required to build and efficiently run a network of modern laboratories (buildings, equipment, IT High barriers infrastructure and solu

  8. Slide 8: Unique platform for global leadership with network effects

    Building a unique platform for global leadership in our attractive high growth markets with large network effects High barriers to entry exist in Eurofins’ markets. Significant investments are required to build and efficiently run modern laboratories. Clients seldom change laboratory supplier.  Con

  9. Slide 9: Hub and spoke laboratory platform in the U.S. food testing

    Since 2015, Eurofins has built a one of a kind hub and spoke laboratories infrastructure platform in the U.S. Food testing market – Hub and spoke model allows for cost-effective and timely delivery of testing results  Eurofins is structuring its unique network of laboratories using the hub and spok

  10. Slide 10: 2020 growth plan half-way update

    2020 growth plan half-way update: building a one of a kind hub and spoke laboratories infrastructure platform for global leadership in our markets – Large hub laboratories capture scale advantage  Building large high throughput laboratory campuses (hubs of the hub and spoke structure) Added or brou

  11. Slide 11: 1987-2017: building a unique global network

    1987 – 2017: In only 30 years we built a unique global network 1987 From 1 laboratory in Nantes (France) in 1987… 2018 4 … to more than 650 laboratories around the world in 2018! > 45,000 employees employees … now present in 45 countries ! Eurofins’ site map as of June 2018 11

  12. Slide 12: Strong Q3 2018 revenue growth and raised objectives

    Eurofins posted strong revenue growth in Q3 2018 and raised its objectives for 2019-2020 Revenues objective for 2020 now set at EUR 5bn Q3/NM 2018: Eurofins continues to make significant progress towards its five year 2015-2020 plan to build a unique, highly efficient hard to replicate state-of-the-

  13. Slide 13: Debt instruments bear low fixed rates for long maturities

    The majority of Eurofins’ debt instruments bear low fixed interest rates for long maturities Bond & Hybrid Capital Maturity Profile Over the years, strict financial discipline has allowed Eurofins to significantly reduce its average cost of funding by refinancing older more expensive debt instrument

  14. Slide 14: Growth, profitability and ROCE objectives

    Growth, Profitability and ROCE are critical objectives Group Profitability Objectives * *  Operating margin developing towards mid- term profitability objective * 1. Start of profit contribution from start-ups 2. Investments in large industrialized laboratories unlock operational leverage  A targe

  15. Slide 15: Upwards revision of objectives to EUR 5bn in 2020

    Upwards revision of objectives to once again double revenues in only 3 years (between 2015 and 2018) instead of 5, and reach €5bn in 2020 vs €4bn originally planned in 2015 for 2020 Illustration of Eurofins’ 2018-2020 growth objectives assuming constant/linear acquisition volume and growth rate each

  16. Slide 16: New warrants program for key leaders

    New warrants program highlights the long-term commitment of Eurofins’ key leaders and their trust in the growth potential of the Group Upside/Downside for warrant holders  In June 2018, Eurofins issued 124,460 warrants exclusively to the Group’s top leaders  Exercise Price €529.65  Purchase Price

  17. Slide 17: Lower cyclicality and organic growth versus TICS peers

    Eurofins has lower cyclicality, generates comparable organic growth to its peers that are less focused on testing for life in each peak of the cycle, and higher growth when the economy slows TICS Organic Revenue Growth (CAGR* if more than 1 year) Source: Eurofins, Company websites, TICS ex ERF = SGS

  18. Slide 18: Outperformance since IPO and equity offerings

    Eurofins has vastly outperformed the market since its IPO and each of its 6 equity offerings (based on share price of EUR 476.40 as of 29 June 2018) Total equity raised in 7 offerings: only EUR 852m, EUR 57m 1997-2000, EUR 496m in 2016 and EUR 299m in 2017 Since IPO Eurofins: +25,941% (31% CAGR) Bes

  19. Slide 19: Strong revenue, profitability and cash flow growth in H1 2018

    Strong revenue, profitability and cash flow growth in H1 2018 Eurofins 3 year Report Card: H1 2015 – H1 2018 CAGR H1 2018: Strong growth & operating momentum  24.8% revenue growth to EUR 1,743m  Over 5% organic growth* in Q2 2018 and close to 5% for H1  EBITDA grew 31.4% to EUR 288m resulting in

  20. Slide 20: Acquisition of Covance Food Solutions

    Eurofins expands its footprint in North America, the UK and Asia with the acquisition of Covance Food Solutions  On August 1st 2018, Eurofins announced the successful closing of the transaction to acquire Covance Food Solutions (CFS) from LabCorp for USD 670m on a cash free debt free basis : CFS is

  21. Slide 21: New number 1 leadership positions in U.S. and Europe

    In H1 2018, Eurofins reached new number 1 leadership positions in the U.S. and Europe thanks to organic growth, strategic acquisitions and start-up laboratories Eurofins has achieved new leadership positions in Food, Environment and Biopharma Product testing:  U.S. – market leader in Food testing –

  22. Slide 22: Acquisition of TestAmerica

    In October 2018, Eurofins acquired TestAmerica, further expanding its environment testing footprint in North America  On October 31st 2018, Eurofins announced the closing of the acquisition of TestAmerica: the leading environment testing laboratory in the U.S., delivering innovative technical exper

  23. Slide 23: Global/European leader in 4 business lines in 2017

    In 2017, Eurofins became the Global/European leader in 4 business lines Eurofins has achieved new leadership positions in four business lines, including:  Global leader in Discovery Pharmacology – achieved through the acquisitions of Villapharma in Spain and DiscoverX which has operations in the US

  24. Slide 24: Strengthening leadership in pharmaceutical discovery services

    Eurofins is strengthening its global leadership in Pharmaceutical Discovery Services 3 historic acquisitions: Pharmaceutical Drug  Cerep Discovery Industry  Panlabs  DDS-Millipore 2 recent acquisitions:  Increasing focus on cost optimization  Growing outsourcing trend  Global pharmaceutical an

  25. Slide 25: Global network of clinical genetics laboratories

    Eurofins is setting up a global network of clinical genetics laboratories  Nowadays, Clinical Genetics is a central element in healthcare and Clinical Diagnostics, contributing to every stage of patient care  Throughout all three of Eurofins’ start-up programs, several large investments in global

  26. Slide 26: Expanding offering in non-invasive prenatal testing

    Eurofins is expanding its global offering in non-invasive prenatal testing (NIPT) In September 2017, Eurofins’ Genoma introduced GeneSafeTM, the first non-invasive prenatal test that screens for both de novo (non-inherited gene mutations) and inherited single-gene disorders.  GeneSafeTM detects ove

  27. Slide 27: Leadership in biopharmaceutical product testing and CDMO entry

    In 2017, Eurofins reinforced its leadership in bio- pharmaceutical product testing and enters the CDMO* industry  On June 13th Eurofins acquired Alphora Research Inc.: a full service CDMO for complex and niche small molecule active pharmaceutical ingredients (APIs)  Alphora is experiencing fast gr

  28. Slide 28: Acquisition of EAG Laboratories

    In 2017, Eurofins expanded its footprint in North America with the acquisition of EAG Laboratories  On December 4th 2017, Eurofins announced the closing of the acquisition of EAG Laboratories: a leading global scientific services company providing analytical testing and consulting solutions to a di

  29. Slide 29: EAG platform trajectory under Eurofins ownership

    EAG Platform Trajectory under Eurofins ownership EV* paid in 780 <900  Attractive EBITDA US$m multiples for bolt-on acquisitions led by 75 ~313 EAG’s leadership 225 6% 238 (single digits) ~216 Revenues  Solid organic growth in US$m mid-to-high single digit top-line and double- digit EBITDA  Syner

  30. Slide 30: European leader in forensics testing

    In 2017, Eurofins becomes the European leader in Forensics Testing services  On October 12th 2017, Eurofins signed an agreement to acquire the Forensics and Security division of LGC (“LGC Forensics”): the largest player in the UK forensics market, a European pioneer in forensics and a significant f

  31. Slide 31: Acquisitions signed and/or closed up to 30/06/2018

    Acquisitions signed and/or closed up to 30/06/2018 Acquisitions signed and/or closed up to 30/06/2018 Tsing Hua (TW) Eichrom Laboratoires (FR) Total Annualised Revenues in 2017 Food Analytica (HU) Protec Bio-testing (FR) Labo Van Poucke (BE) Covance Food Solutions (US)* ELS and City Analysts (IE) PH

  32. Slide 32: Meaningful industry consolidation is underway

    Meaningful industry consolidation is underway Selection of recent significant transactions in the testing industry Date Company Acquirer Geography Sales (€m) EV (€m) EV/Sales (x) EV/EBITDA (x) 2018 September Genewiz Brooks Automation US 102 383 3.8x N/A July Halo Cambrex US 87 353 4.0x 15.7x March B

  33. Slide 33: Start-ups an increasingly attractive investment

    Start-ups an increasingly attractive investment as we leverage our scale and experience 130 laboratories start-ups between 2000 and 2017 Substantial acceleration offers tremendous growth potential 1) Acceleration in laboratories start-up programs  25 start-ups 2000-2009 (Program 1) Where we are bui

  34. Slide 34: Start-ups expected to break even and reach Group profitability

    Start-ups expected to break-even on Year 3 and typically reach Group’s profitability objectives shortly thereafter Illustration Start-ups development: 1) Large investments have short-term dilutive impact on Group’s margins and FCF Example of a typical Eurofins’ start-up: 2) Growth momentum allows st

  35. Slide 35: Our company DNA

    What we are passionate about: Our company DNA Testing for Life Entrepreneurship Everything we do has a positive We are a network of independent, impact on LIFE, HEALTH and the ENVIRONMENT. intrapreneur-led companies and a school for those who aspire to become Results entrepreneurs. Eurofins launches

  36. Slide 36: Family-owned businesses outperform their peers

    Credit Suisse report shows that family-owned businesses outperform their peers* …supported by superior growth and Profitability Revenue and EBITDA growth is stronger, EBITDA margins are higher and cash flow returns are better. Family-owned companies also appear to have a greater focus on innovation

  37. Slide 37: Leader in most markets, building leadership positions

    Eurofins is the leader in most of its markets and continues to build global & local leadership positions* in markets where scale matters New Markets 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Denmark: Food and Environment Testing Sweden, Norway: Food an

  38. Slide 38: Drivers for high long-term above-GDP market growth

    Drivers for high long-term above GDP market growth Secular Underlying Fundamentals General Market Drivers Laboratory Market Drivers Consumer Demand for safe Increasing wealth expectations for pharmaceuticals, quality food and quality of Life protection and clean environment Consolidation of the frag

  39. Slide 39: 80% of world population has limited access to testing laboratories

    An international network of world class, standardised laboratories is attractive for our customers H1 2018 revenue split : N. America 31.7% France 21.2% Germany 11.5% Benelux 6.9% UK & Ireland 6.4% Entry into high-growth Nordic Region 6.3% markets with start ups Others 16.0% & acquisitions 80% of th

  40. Slide 40: Geared towards strong economies and fast-growing markets

    Geared towards strong economies and fast-growing markets Geographical breakdown of Eurofins’ revenues in H1 2018 Germany Benelux Germany North APAC & Germany UK Total France Italy TOTAL Austria Nordics + America Emerging Northern & Excluding Spain Switzerland (Northern Northern markets Europe Irelan

  41. Slide 41: Strategy building long-lasting competitive advantage

    Eurofins’ strategy aims at building long lasting competitive advantage in very attractive markets Leading technology Quality of customer service  Competence Centres & R&D activities  Extensive expertise in local regulations for all major markets, and one-stop contact for  Proprietary technologies

  42. Slide 42: Contents

    Contents  Introduction  Market & Strategic Positioning  Finance & Outlook  Summary  Appendix 42

  43. Slide 43: Food testing market enjoys robust growth drivers

    The Food testing market enjoys robust growth drivers Food scares and Globalisation: Raw Consumers’ Outsourcing of crises, widely materials sourced increasing awareness industry’s covered in the from countries and demand for safe internal or state- media with different QC and high quality food owned

  44. Slide 44: Most comprehensive Food & Feed testing offering

    Eurofins’ Food & Feed testing offering is the most comprehensive in the market Agricultural production, product Production Retail & Distribution development Microbiology Sensorial Dioxins Veterinary drug Vitamins Quality Control residues Authenticity Pesticides Organic residues POPs Labelling GMO My

  45. Slide 45: High profile food scares have expensive consequences

    High profile food scares have expensive consequences for producers… Brand / Year Contamination Impact Cost Source Country 2008 Sanlu/ Melamine in dairy 50,000 infants ill, 6 deaths, global recall of dairy and related products, criminal Unquantified BBC News Fronterra + products charges in China glob

  46. Slide 46: Meeting demands of global players for high quality testing

    Eurofins is meeting the demands of global players for high quality testing  The largest global food & beverage producers and retailers are clients of Eurofins 2017 Sales in 2017 Sales in Food and Beverage Retailers EUR billion EUR billion Nestlé Switzerland 90.1 Wal-Mart Stores USA 485.9 PepsiCo US

  47. Slide 47: Pharma testing market is healthy and full of potential

    The Pharma testing market is both healthy and full of potential Need for big pharma Rapid technological change & companies to expand increasing complexity in testing new drugs pipelines require ongoing investment in technology & expertise  The increasing complexity of clinical trials leads to incre

  48. Slide 48: Underlying trends intact for continued growth

    Underlying trends are intact for continued growth Global Drug R&D Spending (US$ bn)  Pharmaceutical and biotechnology R&D spending is expected to rise to $161 bn in 2018  2017 was a record year in FDA novel drug approvals, the purest measure of biopharma pipeline productivity  Drug approvals fuel

  49. Slide 49: Eurofins Pharma Services

    Eurofins Pharma Services Spanning the entire drug development cycle Genomics Discovery Pre-clinical/ Clinical Development BioPharma Pharmacology Early (Central & Products Development Laboratory/ Manufacturing Testing Bioanalytical) Sequencing Sequencing High-throughput- High-throughput- Pharmacology

  50. Slide 50: 9 of top 10 pharma companies are clients

    9 of the top 10 largest global pharmaceutical companies are clients of Eurofins Eurofins pharma locations Global CRO Market Outlook Top 10 pharma companies Pfizer (US) Sanofi Aventis (FR) GlaxoSmithKline (UK) Novartis (CH) AstraZeneca (UK) Merck & Co (US) Johnson & Johnson (US) Roche (CH) Eli Lilly

  51. Slide 51: Specialized Clinical Diagnostic Network Evolution

    Eurofins Specialized Clinical Diagnostic Network Evolution “Genomics is one of the key technologies enabling personalized medicine…” Establishing platform to deploy genomics expertise for development of innovative clinical diagnostic tests to serve global healthcare community One of the world’s lead

  52. Slide 52: Specialized Clinical Diagnostic Footprint

    Eurofins Specialized Clinical Diagnostic Footprint Establishing leadership in targeted higher-growth niche areas of the clinical testing market Clinical Genetics Japan Clinical Genetics India 52

  53. Slide 53: Environmental testing market continues to grow

    The Environmental testing market continues to grow Rise in Progress in epidemiology contamination & & medicine has identified pollution issues more compounds as toxic  Increasing demand by citizens for a clean environment  EU expanding regulation (e.g. REACH)  Increasingly long list of products i

  54. Slide 54: Eurofins serves all main environmental testing markets

    Eurofins serves all the main environmental testing markets Eurofins is the No.1 environmental testing service provider in the world* Lancaster Environmental Consulting and Testing is the laboratory sampling companies of choice for Fortune 500 are natural partners companies in the USA WATER AIR SOIL

  55. Slide 55: Global trends in regulation support the business

    Global trends in regulation support the business  Strong regulated markets (EU, USA) are still amending and adding regulations  Eastern European rules catching up with EU  Fast development of regulation in Asia  Regulation used for support of trading blocks (e.g. EU, NAFTA, ASEAN) Major pieces o

  56. Slide 56: EU regulations a key driver, e.g. REACH

    EU regulations a key driver for the testing industry – e.g. REACH directive Objectives Examples of affected products or industries  Listing and assessing the safety of 30,000 Metals, resins, acids, solvents, oils, fibres in textile, car chemical substances used by industries in components, toys, co

  57. Slide 57: Outsourcing adds to market growth

    Outsourcing adds to market growth Examples of laboratories outsourced to Eurofins Company Outsourced Activity Country Astellas Astellas Analytical Science Labs Japan Danish Hydrology Inst. Official water reference lab Scandinavia Suez/Sita Envirolab The Netherlands Danish farmers association Steins’

  58. Slide 58: Developing high barriers to entry around businesses

    Eurofins is developing high Barriers to Entry around its businesses Offering a premium quality service … ... and leveraging internal efficiencies  Portfolio: over 150,000 validated methods  Industrialising the laboratory process: – unique in the world and ahead of rationalisation of sites and pers

  59. Slide 59: Contents

    Contents  Introduction  Market & Strategic Positioning  Finance & Outlook  Summary  Appendix 59

  60. Slide 60: Hard-to-replicate world-class infrastructure

    We have built a hard-to-replicate world-class infrastructure Eurofins has been consistently investing more than its peers Source: Eurofins, Company websites TICS ex ERF = SGS, Intertek, Bureau Veritas 60

  61. Slide 61: Midterm objective of 20% adjusted EBITDA margin

    Midterm objective to reach 20% adjusted EBITDA margin, and strengthen cashflow generation In spite of 20 start-ups per year (average past 3 Eurofins Cashflow Expansion Levers years) Separately Disclosed Items (SDI) costs Objectives: reduced significantly as % of Adjusted EBITDA • Reduce relative imp

  62. Slide 62: Allocating cash flow towards building global platform

    Eurofins is allocating part of its cash flow towards building its leading global platform Cashflow expansion levers: cash investments impacting cashflows FCF invested €89m for the future €80m €75m €147m €81m €126m Reported FCF €57m to Equity €100m €19m €51m €46m €49m *Free Cash Flow to Equity - Oper

  63. Slide 63: Network build-out to position for the future

    Network Build-Out to Position for the Future Capex remains driven by network expansion investments Continuous investments in state-of-the-art IT solutions One IT (IT Solutions)  First Generation OneIT deployed in ca. 85% of Food and Environment laboratories  New Generation Genomics and Agroscience

  64. Slide 64: Laboratory network investments

    Laboratory Network Investments: Expansion / Modernization of Laboratory Sites  Since 2005, 120 new/expanded large modern state-of-the-art sites to enable consolidation / closure of smaller or old sites  Total of over 430,000 m2 added or brought to most modern standards between 2005-2017 (over 53,0

  65. Slide 65: Present in countries generating over 83% of world GDP

    Eurofins is already present in countries generating over 83% of the world’s GDP… but still has lots of room to grow International Monetary Fund Eurofins market presence (Estimates as of October 2017) % of world's Environment Biopharma Clinical Country GDP ($tn) Eurofins presence Food testing GDP tes

  66. Slide 66: Heavy investment in high-growth markets and resources

    Heavy investment in high-growth markets and resources for future profits Building corporate resource Bringing recently acquired Network Investments for future size and growth labs to group standards  €1.05 bn total investments in  Recruitment of top  Deploy proprietary IT laboratory network over

  67. Slide 67: Positive trends drive solid operating results

    Positive trends drive solid operating results H1 2018 H1 2017 +/- % +/- % In EUR m except otherwise stated Adjusted1 Separately Statutory Adjusted Separately Statutory Adjusted Reported Results disclosed Results Results disclosed Results Results Results items2 items Revenues 1,743.3 - 1,743.3 1,396.

  68. Slide 68: Solid balance sheet

    Solid Balance Sheet Hybrid  EUR 300m hybrid issued in Jan 2013/Jul 2014, callable at par by Jun 2018 Dec 2017 Eurofins in Jan 2020. Bears a fixed coupon of 7.00% until first call, Euribor 3m + 818 bp thereafter if not called  EUR 300m hybrid issued in April 2015, callable at par by Eurofins  Net

  69. Slide 69: High degree of financial flexibility

    High Degree of Financial Flexibility Strong Balance Sheet as of 30/06/2018  Leverage ratio* remains well below 3.5x Leverage ratio*: max 3.5x  Large financial flexibility with fairly long financing maturity • EUR 300m Eurobond issued in 2013; maturing 2018 • Hybrid capital of EUR 300m; perpetual,

  70. Slide 70: Outlook: becoming world leader in bioanalytical testing

    Outlook: becoming the world leader in the bioanalytical testing market Sustainable Market Growth Drivers + Key Success Factors = Solid Outlook  Food safety & contamination  Unique technological portfolio of 2018 Objectives* issues over 150,000 methods  Over EUR 3.8bn of revenues  EUR 4.0bn of pr

  71. Slide 71: Contents

    Contents  Introduction  Market & Strategic Positioning  Finance & Outlook  Summary  Appendix 71

  72. Slide 72: Conclusion: our sustainable competitive advantage

    Conclusion: our sustainable competitive advantage Best in class technology and quality give best brand High-growth, non-cyclical markets driven by secular protection mega-trends N° 1 or 2 worldwide in most business lines Advancing globalisation but with very few global Network in 45 countries testin

  73. Slide 73: Appendix / Back up slides

    «= eurofins Appendix / Back up slides 73

  74. Slide 74: Full Year 2017 Results Summary

    Full Year 2017 Results Summary 2017 In EUR m except otherwise stated Adjusted1 Separately Statutory Results disclosed Results items2 Revenues 2,971.4 - 2,971.4 EBITDA 556.7 -43.5 513.2 EBITDA Margin (%) 18.7% 17.3% EBITAS 399.6 -62.0 337.5 Net Profit 299.1 -82.4 216.8 Basic EPS (EUR) 15.86 -5.36 10.

  75. Slide 75: Condensed Interim Consolidated Income Statement

    Condensed Interim Consolidated Income Statement H1 2018 H1 2017 Adjusted Separately Reported Adjusted Separately Reported EUR Thousands results disclosed items Results results disclosed items Results Revenues 1,743,315 - 1,743,315 1,396,931 - 1,396,931 Operating costs, net -1,422,965 -32,549 -1,455,

  76. Slide 76: Condensed Interim Consolidated Balance Sheet

    Condensed Interim Consolidated Balance Sheet June 30, December 31, EUR Thousands 2018 2017 Property, plant and equipment 792,556 685,998 Goodwill 2,669,643 2,505,337 Other intangible assets 760,223 735,120 Investments in associates 4,579 5,642 Financial assets and other receivables 48,434 43,942 Def

  77. Slide 77: Condensed Interim Consolidated Cash Flow Statement

    Condensed Interim Consolidated Cash Flow Statement EUR Thousands H1 2018 H1 2017 Cash flows from operating activities Profit before income taxes 122,527 109,691 Adjustments for: Depreciation and amortisation 104,855 84,019 Share-based payment charge and acquisition-related expenses, net 40,834 14,31

  78. Slide 78: Consolidated Income Statement

    Consolidated Income Statement 2017 2016 Adjusted Separately Reported Adjusted Separately Reported EUR Thousands results disclosed items Results results disclosed items Results Revenues 2,971,417 - 2,971,417 2,536,608 - 2,536,608 Operating costs, net -2,414,694 -43,481 -2,458,174 -2,056,984 -18,547 -

  79. Slide 79: EAG entry into Materials and Engineering Sciences markets

    EAG provides Eurofins an entry into the dynamic and growing Materials and Engineering Sciences markets EAG believes that it holds the N°1 position in both Materials and Engineering Sciences markets, in the USA.  Materials and Engineering Sciences represent over 50% of EAG’s total revenue. The Mater

  80. Slide 80: Sales and profits increase after acquisition and integration

    Post acquisition and integration into Eurofins, both sales and profits often increase significantly Illustration Growth drivers post acquisition: 1) Sales increase through cross selling of Actual example of an acquired lab: Eurofins lab specialities internationally 2) Cost reduction – focus on most

  81. Slide 81: Shareholder Returns: TICS & Clinical Diagnostics Companies

    Shareholder Returns: TICS & Clinical Diagnostics Companies Based on share prices as of close 29.12.2017 Shareholder Returns Based on share prices Total Shareholder Returns 31-Dec-11 31-Dec-12 31-Dec-13 31-Dec-14 31-Dec-15 31-Dec-16 31-Dec-17 31-Dec-11 31-Dec-12 31-Dec-13 31-Dec-14 31-Dec-15 31-Dec-1

  82. Slide 82: Shareholder Returns: TICS & Clinical Diagnostics Companies

    Shareholder Returns: TICS & Clinical Diagnostics Companies Historical Share Price Development (Y vs Y-1) Compounded Growth 2Y 3Y 4Y 5Y 5Y 31-Dec-13 31-Dec-14 31-Dec-15 31-Dec-16 31-Dec-17 Growth 2016-2017 2015-2017 2014-2017 2013-2017 Eurofins 60.4% 7.9% 51.8% 25.8% 25.3% 314.4% 26% 34% 27% 33% SGS

  83. Slide 83: Strong financial discipline at all times

    Strong financial discipline at all times Average net debt/L12M EBITDA 21 acquisitions with total annualized revenue About 60 acquisitions with total annualized contribution of over EUR 570m. revenue contribution of ca. EUR 700m. Entry into 3 new countries Entry into 5 new countries 10 start-ups 30 s

Eurofins Scientific — Investor Presentation (December 2018) on 6ix